TY - JOUR
T1 - Helicobacter pylori first-line and rescue treatments in patients allergic to penicillin
T2 - Experience from the European Registry on H pylori management (Hp-EuReg)
AU - Hp-EuReg Investigators
AU - Nyssen, Olga P
AU - Pérez-Aisa, Ángeles
AU - Tepes, Bojan
AU - Rodrigo-Sáez, Luis
AU - Romero, Pilar M
AU - Lucendo, Alfredo
AU - Castro-Fernández, Manuel
AU - Phull, Perminder
AU - Barrio, Jesús
AU - Bujanda, Luis
AU - Ortuño, Juan
AU - Areia, Miguel
AU - Brglez Jurecic, Natasa
AU - Huguet, José María
AU - Alcaide, Noelia
AU - Voynovan, Irina
AU - María Botargues Bote, José
AU - Modolell, Inés
AU - Pérez Lasala, Jorge
AU - Ariño, Inés
AU - Jonaitis, Laimas
AU - Dominguez-Cajal, Manuel
AU - Buzas, György
AU - Lerang, Frode
AU - Perona, Monica
AU - Bordin, Dmitry
AU - Axon, Toni
AU - Gasbarrini, Antonio
AU - Marcos Pinto, Ricardo
AU - Niv, Yaron
AU - Kupcinskas, Limas
AU - Tonkic, Ante
AU - Leja, Marcis
AU - Rokkas, Theodore
AU - Boyanova, Lyudmila
AU - Shvets, Oleg
AU - Venerito, Marino
AU - Bytzer, Peter
AU - Goldis, Adrian
AU - Simsek, Ilkay
AU - Lamy, Vincent
AU - Przytulski, Krzysztof
AU - Kunovský, Lumír
AU - Capelle, Lisette
AU - Milosavljevic, Tomica
AU - Caldas, María
AU - Garre, Ana
AU - Mégraud, Francis
AU - O'Morain, Colm
AU - Gisbert, Javier P
N1 - © 2020 John Wiley & Sons Ltd.
PY - 2020/6
Y1 - 2020/6
N2 - BACKGROUND: Experience in Helicobacter pylori eradication treatment of patients allergic to penicillin is very scarce. A triple combination with a PPI, clarithromycin (C), and metronidazole (M) is often prescribed as the first option, although more recently the use of a quadruple therapy with PPI, bismuth (B), tetracycline (T), and M has been recommended.AIM: To evaluate the efficacy and safety of first-line and rescue treatments in patients allergic to penicillin in the "European Registry of H pylori management" (Hp-EuReg).METHODS: A systematic prospective registry of the clinical practice of European gastroenterologists (27 countries, 300 investigators) on the management of H pylori infection. An e-CRF was created on AEG-REDCap. Patients with penicillin allergy were analyzed until June 2019.RESULTS: One-thousand eighty-four patients allergic to penicillin were analyzed. The most frequently prescribed first-line treatments were as follows: PPI + C + M (n = 285) and PPI + B + T + M (classic or Pylera® ; n = 250). In first line, the efficacy of PPI + C + M was 69%, while PPI + B + T + M reached 91% (P < .001). In second line, after the failure of PPI + C + M, two rescue options showed similar efficacy: PPI + B + T + M (78%) and PPI + C + levofloxacin (L) (71%) (P > .05). In third line, after the failure of PPI + C + M and PPI + C + L, PPI + B + T + M was successful in 75% of cases.CONCLUSION: In patients allergic to penicillin, a triple combination with PPI + C + M should not be generally recommended as a first-line treatment, while a quadruple regimen with PPI + B + T + M seems to be a better option. As a rescue treatment, this quadruple regimen (if not previously prescribed) or a triple regimen with PPI + C + L could be used but achieved suboptimal (<80%) results.
AB - BACKGROUND: Experience in Helicobacter pylori eradication treatment of patients allergic to penicillin is very scarce. A triple combination with a PPI, clarithromycin (C), and metronidazole (M) is often prescribed as the first option, although more recently the use of a quadruple therapy with PPI, bismuth (B), tetracycline (T), and M has been recommended.AIM: To evaluate the efficacy and safety of first-line and rescue treatments in patients allergic to penicillin in the "European Registry of H pylori management" (Hp-EuReg).METHODS: A systematic prospective registry of the clinical practice of European gastroenterologists (27 countries, 300 investigators) on the management of H pylori infection. An e-CRF was created on AEG-REDCap. Patients with penicillin allergy were analyzed until June 2019.RESULTS: One-thousand eighty-four patients allergic to penicillin were analyzed. The most frequently prescribed first-line treatments were as follows: PPI + C + M (n = 285) and PPI + B + T + M (classic or Pylera® ; n = 250). In first line, the efficacy of PPI + C + M was 69%, while PPI + B + T + M reached 91% (P < .001). In second line, after the failure of PPI + C + M, two rescue options showed similar efficacy: PPI + B + T + M (78%) and PPI + C + levofloxacin (L) (71%) (P > .05). In third line, after the failure of PPI + C + M and PPI + C + L, PPI + B + T + M was successful in 75% of cases.CONCLUSION: In patients allergic to penicillin, a triple combination with PPI + C + M should not be generally recommended as a first-line treatment, while a quadruple regimen with PPI + B + T + M seems to be a better option. As a rescue treatment, this quadruple regimen (if not previously prescribed) or a triple regimen with PPI + C + L could be used but achieved suboptimal (<80%) results.
U2 - 10.1111/hel.12686
DO - 10.1111/hel.12686
M3 - Article
C2 - 32173974
SN - 1083-4389
VL - 25
JO - Helicobacter
JF - Helicobacter
IS - 3
M1 - e12686
ER -